{'fraction_non_alphanumeric': 0.029036004645760744, 'fraction_numerical': 0.009291521486643438, 'mean_word_length': 5.481203007518797, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Research progress of ischemic hepatitis].

Ischemic hepatitis, also known as hypoxic hepatitis or shock liver, refers to liver cell damage without any known cause of acute hepatitis, and is characterized by transient elevation of transaminase levels (20 times higher than normal value).The incidence of the disease is about 2.5% to 10%, and the hospital mortality rate is greater than 50%. Current research suggests that there are many risk factors for the disease, including systemic hypotension, low cardiac output, sepsis and respiratory distress, but eventually it will manifest as hepatocyte dysfunction. Unfortunately, the mortality rate related with hypotension is high, and the key to treatment is to correct hemodynamic disorders. This article reviews the research progress in the etiology, mechanism and clinical manifestations of ischemic hepatitis.